CompletedNot Applicable

Hyperthermia in Fibromyalgia Syndrome

Germany41 participantsStarted 2020-11-12

Plain-language summary

This study will examine the effectiveness of water-filtered whole-body hyperthermia during an outpatient setting in patients with fibromyalgia. The duration of the study is about 3 weeks with two treatment units per week and a passive period (follow-up measurement) of 24 weeks after the outpatient setting.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * confirmed diagnosis of fibromyalgia (FSQ) * Pain VAS \>= 4,0 * Signed declaration of consent Exclusion Criteria: * Participation in other clinical studies * Contraindications for hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women) * Acute and / or feverish microbial infections * Patients with severe somatic, rheumatic concomitant endocrine or neurological diseases, in particular neurological diseases associated with cognitive disorders, severe liver or kidney and cardiac diseases * Patients who are permanently treated with opioids, cannabis, immunosuppressive drugs (e.g. corticoids, immunosuppressants) or alpha/beta-A(nta)gonists due to a disease from the group described above * Patients with pain due to a serious psychiatric illness (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) and serious systemic or neurological disorders

What they're measuring

Brief Pain Inventory (BPI) - Intensity of pain (Numeric Rating Scale, NRS)

Timeframe: Week 0

Brief Pain Inventory (BPI) - Intensity of pain (Numeric Rating Scale, NRS)

Timeframe: Week 4

Trial details

NCT IDNCT05135936

SponsorJost Langhorst

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-19

View on ClinicalTrials.gov More Fibromyalgia trials